Supplementary Figure S2 from Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine
Year: 2025
Type: supplementary-materials
Abstract: A. Gating strategy applied on PBMCs samples evaluated by flow cytometry. CD8+ T cell memory was defined based on the expression of CD45RA and CCR7 (CD197). Cell surface phenotype (PD-1, CD39, and CD69) and intracellular activation (Ki-67) markers were quantified on CD8+ effector T cell (TEFF) based on indicated gates. B, CD8+ naïve and memory T cells in long-and short-survivors quantified before and after the treatment. C, Representative flow cytometry plots showing CD8+ T cells activation in PBMC samples from a short survivor. PD-1+ Ki-67+ expression on CD8+ T cells compared before and after the treatment.
Authors: Casey L. O'Connell, Maria R. Baer, Andreas Due Ørskov, Sunil Kumar Saini, Vu H. Duong, Patricia Kropf, Jakob Werner Hansen, Denice Tsao-Wei, Hyo Sik Jang, Ashkan Emadi, Staffan Holmberg-Thyden, Jack Cowland, Brett T. Brinker, Kristin Horwood, Ryan Burgos, Galen Hostetter, Benjamin A. Youngblood, Sine Reker Hadrup, Jean-Pierre Issa, Peter Jones, Stephen B. Baylin, Imran Siddiqi, Kirsten Grønbaek
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4416626602
Cites:
Cited by:
Related to: